X-Care Makes Major Investment in SGRT from Vision RT

13th September 2019
aandersen

London, 13 September 2019 Leading radiotherapy service provider, X-Care Praxis für Radiologie und Nuklearmedizin, has purchased a total of 8 AlignRT systems from Vision RT for use in 4 of its treatment sites across Germany.

X-Care evaluated different SGRT technologies before choosing Vision RT, with the service and support that Vision RT offer being one of the key factors in the decision. The systems will be used initially for standard procedures, with a view to expanding to stereotactic radiosurgery in the future.

“The choice to deliver SGRT in every clinic is becoming more and more popular,” says Norman Smith, CEO at Vision RT. “We thank X-Care for this significant endorsement of our product, and also the level of customer care we provide to ensure all our users are delighted with our products.”

X-Care use Elekta linear accelerators across their sites, and the strong integration and easy workflow of AlignRT with Elekta systems also played a part in X-Care’s decision.

The AlignRT system tracks a patient’s position before and during radiation therapy, to aid setup and treatment accuracy, and can be used for a wide range of conditions including breast, brain, lung, liver, sarcoma, head and neck and other cancers. In some cases, AlignRT technology enables users to eliminate the need for patients to have permanent marks tattooed on their bodies which historically was used to ensure accurate treatment.

About Vision RT

Vision RT defines the standard of care in Surface Guided Radiation Therapy. We provide superior solutions for the radiotherapy market, with products installed in many of the leading treatment centers in the world, including around 70% of the 50 US News “Best Hospitals for Cancer”. With more than 70 granted patents plus more than 50 pending, we continue to innovate in the radiation oncology space and are committed to making SGRT the standard of care for all patients, worldwide.

Vision RT is part of the William Demant Invest (WDI) family, a leading Danish Medtech investor with a long-term investment perspective. The companies in WDI employ more than 18,000 people, with a total revenue of more than $3 billion.